MedTrace Logo

Long-term Oral Esomeprazole for Prevention of Peptic Ulcer Rebleeding in High-risk Patients

NCT02456012 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 268

Last updated 2022-02-22

No results posted yet for this study

Summary

The purpose of this study is to determine whether a long-term prophylactic use of esomeprazole 20 mg twice daily or once daily has prevention effectiveness in reducing the recurrence of peptic ulcer bleeding after ulcer healed with 16-week oral esomeprazole therapy in high-risk patients whose Rockall score ≥ 6.

Conditions

  • Peptic Ulcer Hemorrhage

Interventions

DRUG

oral esomeprazole 20 mg twice daily

for 36 weeks

DRUG

oral esomeprazole 20 mg once daily

for 36 weeks

Sponsors & Collaborators

  • Hsiu-Chi Cheng

    lead OTHER

Principal Investigators

  • Bor-Shyang Sheu, MD · National Cheng-Kung University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02456012 on ClinicalTrials.gov